Radius Stock Rides Rollercoaster After ASBMR Bone Data
This article was originally published in Scrip
Radius Health Inc. continues to report positive results for its osteoporosis therapy abaloparatide, but the company's stock has been on a somewhat bumpy ride since results were presented at the recent American Society of Bone and Mineral Research (ASBMR) meeting.
You may also be interested in...
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.